Ali Bonakdar Tehrani1, Rachel Mosher Henke1, Mir M Ali2, Ryan Mutter3, Tami L Mark4. 1. Truven Health Analytics, An IBM Company, United States. 2. Substance Abuse & Mental Health Services Administration, Center for Behavioral Health Statistics & Quality, 5600 Fishers Lane, Rockville, MD 20852, United States. Electronic address: mir.ali@samhsa.hhs.gov. 3. Substance Abuse & Mental Health Services Administration, Center for Behavioral Health Statistics & Quality, Rockville, MD, United States. 4. RTI International, Washington D.C., United States.
Abstract
OBJECTIVES: To calculate trends in adult average days' supply for six commonly prescribed opioids: hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone, and tapentadol to assess whether physicians changed prescribing practices at the time of the intensifying epidemic. METHODS: We used 2005-2015 Truven Health MarketScan Commercial Claims and Encounters data to measure trends in opioid average days' supply among commercially insured individuals and 2005-2014 MarketScan Multi-State Medicaid data to measure trends in opioid average days' supply among Medicaid beneficiaries. RESULTS: For Medicaid, we found an increase in days' supply for all drugs except morphine. The largest percentage increase was for oxycodone, which increased 4.5days (37%). Opioid days' supply for individuals with commercial insurance exhibited similar but steeper trends. The largest increase was also for oxycodone, which increased 6days (56%). Between 2013 and 2015, when the opioid epidemic had begun to be widely publicized, there was no decline in the median days supplied for any of the opioids. CONCLUSIONS: Our results find that days' supply of opioids are increasing despite public health campaigns and media attention on the risks of opioid prescribing. More effective interventions to curb opioid prescribing are needed to reverse these trends. Published by Elsevier Ltd.
OBJECTIVES: To calculate trends in adult average days' supply for six commonly prescribed opioids: hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone, and tapentadol to assess whether physicians changed prescribing practices at the time of the intensifying epidemic. METHODS: We used 2005-2015 Truven Health MarketScan Commercial Claims and Encounters data to measure trends in opioid average days' supply among commercially insured individuals and 2005-2014 MarketScan Multi-State Medicaid data to measure trends in opioid average days' supply among Medicaid beneficiaries. RESULTS: For Medicaid, we found an increase in days' supply for all drugs except morphine. The largest percentage increase was for oxycodone, which increased 4.5days (37%). Opioid days' supply for individuals with commercial insurance exhibited similar but steeper trends. The largest increase was also for oxycodone, which increased 6days (56%). Between 2013 and 2015, when the opioid epidemic had begun to be widely publicized, there was no decline in the median days supplied for any of the opioids. CONCLUSIONS: Our results find that days' supply of opioids are increasing despite public health campaigns and media attention on the risks of opioid prescribing. More effective interventions to curb opioid prescribing are needed to reverse these trends. Published by Elsevier Ltd.
Authors: Jennifer C Thompson; Yuko M Komesu; Fares Qeadan; Peter C Jeppson; Sara B Cichowski; Rebecca G Rogers; Aurélien J Mazurie; Anastasiya Nestsiarovich; Christophe G Lambert; Gena C Dunivan Journal: Am J Obstet Gynecol Date: 2018-07-11 Impact factor: 8.661
Authors: Katherine Hadlandsmyth; Hilary J Mosher; Mark W Vander Weg; Amy M O'Shea; Kimberly D McCoy; Brian C Lund Journal: Pharmacol Res Perspect Date: 2020-04
Authors: Courtney N Maierhofer; Shabbar I Ranapurwala; Bethany L DiPrete; Naoko Fulcher; Christopher L Ringwalt; Paul R Chelminski; Timothy J Ives; Nabarun Dasgupta; Vivian F Go; Brian W Pence Journal: Pain Med Date: 2021-12-11 Impact factor: 3.637